Literature DB >> 24661744

Analysis of 35 cases of Xanthogranulomatous pyelonephritis.

Ben Addison1, Homayoun Zargar, Nikola Lilic, David Merrilees, Michael Rice.   

Abstract

BACKGROUND: To retrospectively determine key demographic and clinical features of 35 patients with Xanthogranulomatous pyelonephritis (XGP) in a New Zealand setting and to compare it with the existing literature.
METHODS: A retrospective review of patients having a confirmed diagnosis of XGP on histopathology examination was performed. Key clinical and demographic features were analysed and compared with the published literature.
RESULTS: XGP was diagnosed in 35 patients over a 12-year (2001-2013) period in Auckland Public Hospital. Ninety-one percent of the patients were female. The population had significantly higher numbers of Maori and Pacific Island patients compared with the general population (74%). Staghorn calculi were the most common cause (51.4%) with obstructing ureteric calculi as the next most common (22.9%) cause. Twenty percent of cases were not thought to be XGP prior to nephrectomy (suspicious renal mass). Thirteen (38%) patients suffered serious complications post-operatively (Clavien 3-5).
CONCLUSION: XGP is a rare chronic inflammatory condition that appears to be overrepresented by Maori and Pacific islanders in our cohort when compared with the overall patient pool. Surgical treatment is associated with significant morbidity but remains the only definitive option. Obesity and other conditions associated with metabolic syndrome may coexist at the time of presentation and may be contributing factors to the development of XGP and poor outcomes associated with it.
© 2014 Royal Australasian College of Surgeons.

Entities:  

Keywords:  Maori; Xanthogranulomatous pyelonephritis; chronic inflammation; stone

Mesh:

Year:  2014        PMID: 24661744     DOI: 10.1111/ans.12581

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  9 in total

1.  Pyeloduodenal fistula complicating xanthogranulomatous pyelonephritis.

Authors:  Maude Laberge; Girish S Kulkarni; Boraiah Sreeharsha
Journal:  Int Urol Nephrol       Date:  2018-05-21       Impact factor: 2.370

Review 2.  Xanthogranulomatous pyelonephritis: a review and meta-analysis with a focus on management.

Authors:  Paul Gravestock; Lauren Moore; Chris Harding; Rajan Veeratterapillay
Journal:  Int Urol Nephrol       Date:  2022-07-09       Impact factor: 2.266

3.  Case report: Xanthogranulomutous pyelonephritis presenting as "Wilms' tumor".

Authors:  Shakilu Iumanne; Aika Shoo; Larry Akoko; Patricia Scanlan
Journal:  BMC Urol       Date:  2016-07-07       Impact factor: 2.264

4.  A 13-Month-Old With Xanthogranulomatous Pyelonephritis With Features of Renal Malakoplakia.

Authors:  Tova Appleson; Asma Sharif; Suman Setty; Dennis Liu; Shihtien Wang; Robert Kanard; Kimberly Czech
Journal:  J Investig Med High Impact Case Rep       Date:  2016-02-05

5.  A Case of Xanthogranulomatous Pyelonephritis Associated with Renoduodenal Fistula.

Authors:  R Conor Holton-Burke; Mini Varughese
Journal:  Case Rep Med       Date:  2017-03-23

6.  Xanthogranulomatous pyelonephritis: A case report.

Authors:  Christian Morales; Valentina Opazo; Cristóbal Bassa; Luis López; Fernando Araos; Patricio Madrid; Ignacio Morales
Journal:  Urol Case Rep       Date:  2018-05-11

7.  Infliximab-Associated Xanthogranulomatous Pyelonephritis: A Rare Complication.

Authors:  Adnan Alzanbagi; Ghadeer A Alhazmi; Shuruq Alghamdi; Ghaida Alosaimi; Mohammed K Shariff
Journal:  Cureus       Date:  2022-01-09

8.  Xanthogranulomatous pyelonephritis combined with emphysematous pyelonephritis: A rare case report.

Authors:  Emadoddin Moudi; Mohammadmehdi Darzi; Sepehr Ramzani; Abazar Akbarzadeh Pasha
Journal:  Caspian J Intern Med       Date:  2021

Review 9.  Nephron-sparing management of Xanthogranulomatous pyelonephritis presenting as spontaneous renal hemorrhage: a case report and literature review.

Authors:  William Keith Ballentine; Fernandino Vilson; Raymond B Dyer; Majid Mirzazadeh
Journal:  BMC Urol       Date:  2018-06-05       Impact factor: 2.264

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.